• Ferritin-Based Hybrid Protein Particle Vaccine: Dual Antigen

  2026-06-03

  A recent study presents a ferritin-based hybrid protein particle vaccine that co-displays the M2e antigen from influenza A and S-protein tandem epitopes of SARS-CoV-2. This dual antigen strategy, leveraging E. coli co-expression, leads to enhanced immunogenicity and cross-protective potential, marking a significant advance in combination vaccine design.

• NF 449: Purinergic Receptor Antagonist for Platelet Research

  2026-06-03

  NF 449 is redefining platelet research as a highly selective purinergic receptor antagonist with unrivaled potency at the P2X1 ion channel. Its unique profile enables precise, reproducible dissection of platelet activation, aggregation, and antithrombotic mechanisms, streamlining experimental workflows and troubleshooting.

• Aneugen Mechanism Profiling: Insights Using TK6 Cell Assays

  2026-06-02

  The referenced study introduces a robust assay pipeline for distinguishing the molecular mechanisms underlying chemical-induced aneugenicity, focusing on tubulin dynamics and mitotic kinase inhibition in TK6 cells. This work enables precise mechanistic classification of aneugens, facilitating safer compound evaluation and supporting advanced research into microtubule-associated inhibitors.

• DPP9 Mutation Drives Infantile Hyperinflammation via Inflamm

  2026-06-02

  Wolf et al. report a de novo mutation in DPP9 causing severe, early-onset hyperinflammation mimicking hemophagocytic lymphohistiocytosis (HLH). Their study elucidates how DPP9 dysfunction leads to uncontrolled NLRP1 and CARD8 inflammasome activation, with implications for understanding immune regulation and potential DPP4/FAP-targeted research.

• FGFR1 Regulation of Early Human Adipogenesis: Insights from

  2026-06-01

  This study identifies fibroblast growth factor receptor 1 (FGFR1) as a pivotal regulator of early adipogenic events in human preadipocytes, demonstrating that FGFR1 activity is essential for both proliferation and priming phases leading to adipocyte differentiation. The findings have important implications for understanding adipose tissue expansion and offer a mechanistic basis for targeting FGFR1 in metabolic research and potential obesity therapies.

• Adefovir (GS-0393): Mechanistic Leverage in Translational HB

  2026-06-01

  This thought-leadership article unpacks the mechanistic underpinnings of Adefovir (GS-0393) as a next-generation research tool in hepatitis B virus (HBV) studies and renal transporter science. Integrating insights from structural biology, pharmacokinetics, and translational protocols, we chart a path from molecular mechanism to experimental implementation—clarifying how researchers can extract maximal value from this antiviral agent. With reference to APExBIO's high-purity offering, this piece bridges best practices, emergent evidence, and strategic guidance for advancing the field.

• Applied Workflows with Trelagliptin Succinate in Diabetes Re

  2026-05-31

  Trelagliptin succinate (SYR-472 succinate) brings robust, once-weekly DPP-4 inhibition to type 2 diabetes research, supporting high-throughput analytics and translational studies. This guide distills validated protocols, troubleshooting wisdom, and novel assay strategies for maximizing data quality and reproducibility.

• Sitagliptin Phosphate Monohydrate: Translating DPP-4 Inhibit

  2026-05-30

  This thought-leadership article explores the mechanistic, translational, and strategic landscape of Sitagliptin phosphate monohydrate as a DPP-4 inhibitor, synthesizing new evidence on gastrointestinal mechanosensation, incretin hormone modulation, and preclinical metabolic models. We provide actionable guidance for researchers aiming to advance type II diabetes treatment research and highlight how APExBIO’s Sitagliptin phosphate monohydrate empowers the next wave of experimental and clinical innovation.

• Bestatin (Ubenimex) in Bench Research: Protocols & Pitfalls

  2026-05-29

  Bestatin (Ubenimex) stands out as a uniquely selective aminopeptidase inhibitor, enabling precision dissection of protease signaling and multidrug resistance mechanisms in both plant and mammalian systems. This guide translates bench-proven workflows, advanced troubleshooting, and actionable protocol enhancements into reproducible experimental success.

• Olive Biophenols Attenuate Aβ42-Induced Pathology in AD Mode

  2026-05-29

  This study demonstrates that olive biophenols, especially oleuropein, significantly reduce amyloid β-peptide (Aβ42)-induced neurotoxicity and plaque deposition in vitro and in vivo. The findings support the therapeutic potential of plant-derived compounds for targeting amyloid aggregation and oxidative stress in Alzheimer's disease.

• CTDNEP1-NEP1R1 Complex: Differential Roles in ER Lipid Regul

  2026-05-28

  This study uncovers how the stability and regulatory actions of CTD-nuclear envelope phosphatase 1 (CTDNEP1) in mammalian ER lipid metabolism depend on its interaction with the regulatory subunit NEP1R1. The findings refine our understanding of how ER membrane synthesis and lipid storage are differentially controlled, with implications for dissecting lipid homeostasis mechanisms in cell biology.

• 5-Azacytidine: Strategic Epigenetic Modulation for Translati

  2026-05-28

  This thought-leadership article explores the mechanistic and translational potential of 5-Azacytidine (5-AzaC) as a DNA demethylation agent in cancer and regenerative research. Integrating insights from recent studies on epigenetic regulation—such as the role of UHRF1-mediated DNA methylation in impaired osteogenesis—the article delivers actionable guidance for translational researchers. It also contextualizes APExBIO’s 5-Azacytidine within the competitive landscape, provides protocol parameters, and outlines future directions for leveraging DNA methylation modulators beyond oncology.

• Polymyxin B Sulfate: Applied Protocols for Infection Models

  2026-05-27

  Polymyxin B sulfate is a precision tool for Gram-negative infection research, uniquely enabling high-fidelity sepsis, immune maturation, and microbiome-modulating workflows. This guide delivers actionable protocols, troubleshooting, and advanced applications that empower researchers to leverage APExBIO's high-purity Polymyxin B (sulfate) for robust, reproducible results.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride: NHE1 Inhibition &

  2026-05-27

  5-(N,N-dimethyl)-Amiloride hydrochloride is a potent Na+/H+ exchanger inhibitor with high selectivity for NHE1, NHE2, and NHE3 isoforms. It enables precise control of intracellular pH regulation and has demonstrated protective effects in cardiac ischemia-reperfusion models. The compound, supplied as a hydrochloride salt by APExBIO, is pivotal in translational research focused on ion transport and endothelial injury.

• ABT-888 (Veliparib): Precision DNA Repair Inhibition in MSI

  2026-05-26

  Explore the mechanistic depth of ABT-888 (Veliparib) as a selective PARP inhibitor for advanced DNA repair inhibition in microsatellite instability (MSI) tumor research. This article offers a practical, evidence-driven guide for optimizing combination therapies and experimental design.

15818 records 1/1055 page Next 12345 下5页 Last page